KR20240142514A - 치료진단적 폴레이트 접합체 - Google Patents

치료진단적 폴레이트 접합체 Download PDF

Info

Publication number
KR20240142514A
KR20240142514A KR1020247028953A KR20247028953A KR20240142514A KR 20240142514 A KR20240142514 A KR 20240142514A KR 1020247028953 A KR1020247028953 A KR 1020247028953A KR 20247028953 A KR20247028953 A KR 20247028953A KR 20240142514 A KR20240142514 A KR 20240142514A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
present disclosure
radiometal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028953A
Other languages
English (en)
Korean (ko)
Inventor
피올라 그뢴
마리-루이스 렌츠
루돌프 모저
로거 쉬블리
크리스티나 막달레나 뮐러
마르티나 베네소바
파트리샤 구지크
루이자 마리아 데베를레
안나 엘리자베트 벡커
자라 도리나 부쓸링거
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20240142514A publication Critical patent/KR20240142514A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247028953A 2022-02-01 2023-01-30 치료진단적 폴레이트 접합체 Pending KR20240142514A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154653 2022-02-01
EP22154653.4 2022-02-01
PCT/EP2023/052116 WO2023148115A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (1)

Publication Number Publication Date
KR20240142514A true KR20240142514A (ko) 2024-09-30

Family

ID=80119142

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028953A Pending KR20240142514A (ko) 2022-02-01 2023-01-30 치료진단적 폴레이트 접합체

Country Status (9)

Country Link
US (1) US20250108138A1 (https=)
EP (1) EP4472676A1 (https=)
JP (1) JP2025504028A (https=)
KR (1) KR20240142514A (https=)
CN (1) CN118660723A (https=)
AU (1) AU2023214599A1 (https=)
CA (1) CA3243526A1 (https=)
IL (1) IL314507A (https=)
WO (1) WO2023148115A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物

Also Published As

Publication number Publication date
AU2023214599A1 (en) 2024-09-19
IL314507A (en) 2024-09-01
CN118660723A (zh) 2024-09-17
US20250108138A1 (en) 2025-04-03
JP2025504028A (ja) 2025-02-06
EP4472676A1 (en) 2024-12-11
CA3243526A1 (en) 2023-08-10
WO2023148115A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
JP7393485B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
JP2019520328A (ja) Ｐｅｔイメージング用免疫修飾因子
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
US20250108138A1 (en) Theragnostic folate conjugates
US20250127938A1 (en) Theragnostic folate conjugates
US10449261B2 (en) Compositions targeting radiation-induced molecules and methods of use thereof
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
HK40110380A (zh) 治疗诊断学叶酸酯缀合物
HK40109744A (zh) 治疗诊断学叶酸酯缀合物
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
WO2025191096A1 (en) Bicyclic peptide
HK40054611A (en) Novel tumor antigen binding agents and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000